Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.10 Insider Own- Shs Outstand9.73M Perf Week3.69%
Market Cap6.81M Forward P/E- EPS next Y-2.23 Insider Trans- Shs Float2.39M Perf Month-12.03%
Income-20.36M PEG- EPS next Q-0.30 Inst Own0.18% Short Float / Ratio2.09% / 0.04 Perf Quarter-51.73%
Sales0.00M P/S- EPS this Y87.20% Inst Trans-72.07% Short Interest0.05M Perf Half Y-74.99%
Book/sh-0.85 P/B- EPS next Y-24.91% ROA-79.35% Target Price9.48 Perf Year-82.50%
Cash/sh0.65 P/C1.08 EPS next 5Y- ROE-1160.54% 52W Range0.62 - 9.02 Perf YTD-82.29%
Dividend- P/FCF- EPS past 5Y36.53% ROI-4678.09% 52W High-92.24% Beta1.04
Dividend %- Quick Ratio0.81 Sales past 5Y0.00% Gross Margin- 52W Low12.89% ATR0.07
Employees- Current Ratio0.81 Sales Q/Q- Oper. Margin0.00% RSI (14)43.11 Volatility10.38% 8.72%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.01 Prev Close0.70
ShortableYes LT Debt/Eq- EarningsSep 27 AMC Payout- Avg Volume1.12M Price0.70
Recom2.00 SMA20-3.80% SMA50-15.53% SMA200-69.83% Volume8,089 Change0.43%
Nov-17-23 05:15PM
Oct-30-23 01:20AM
Oct-27-23 05:15PM
Sep-27-23 05:45PM
Sep-25-23 12:09PM
01:30AM Loading…
Sep-19-23 01:40AM
Sep-14-23 01:30AM
Sep-11-23 01:20AM
Sep-04-23 05:30PM
Aug-16-23 01:15AM
Aug-08-23 01:20AM
Jul-20-23 01:20AM
Jul-19-23 02:20AM
Jul-18-23 01:20AM
01:00AM Loading…
Jul-10-23 01:00AM
Jun-19-23 01:30AM
Jun-16-23 05:20PM
Jun-05-23 02:20AM
May-26-23 02:30AM
May-25-23 02:20AM
May-15-23 02:20AM
May-11-23 02:20AM
May-10-23 02:10PM
May-09-23 02:20AM
May-02-23 02:20AM
Apr-28-23 05:30PM
Apr-19-23 02:20AM
Apr-18-23 03:45AM
05:20PM Loading…
Mar-30-23 05:20PM
Mar-27-23 02:20AM
Mar-17-23 03:20AM
Mar-09-23 02:20AM
Mar-02-23 02:00AM
Feb-27-23 02:20AM
Feb-23-23 02:20AM
Feb-02-23 02:20AM
Jan-31-23 02:20AM
Jan-19-23 02:00AM
Jan-12-23 02:20AM
Jan-05-23 02:20AM
Dec-01-22 02:30AM
Nov-03-22 09:13AM
Oct-31-22 07:10PM
Oct-26-22 02:45AM
Sep-15-22 02:30AM
Sep-13-22 02:20AM
Sep-07-22 07:05AM
Jun-30-22 05:20PM
Jun-27-22 05:45PM
Jun-22-22 05:30PM
Jun-03-22 05:20PM
May-12-22 02:20AM
Apr-19-22 02:20AM
Apr-07-22 08:11AM
Apr-05-22 05:30PM
Mar-16-22 03:20AM
Feb-03-22 09:03AM
Dec-22-21 05:20PM
Dec-16-21 02:30AM
Nov-22-21 05:20PM
Nov-15-21 03:08PM
Oct-29-21 02:55AM
Oct-06-21 05:00PM
Oct-04-21 05:00PM
Sep-29-21 02:00AM
Sep-17-21 02:00AM
Sep-15-21 02:00AM
Sep-14-21 02:00AM
Sep-09-21 02:00AM
Aug-16-21 08:36AM
Aug-13-21 05:00PM
Aug-02-21 06:24AM
Jul-19-21 05:00PM
Jul-12-21 12:53PM
Jul-08-21 02:00AM
Jun-30-21 05:00PM
Jun-18-21 08:00PM
May-12-21 02:00AM
May-11-21 02:00AM
Apr-30-21 02:00AM
Apr-29-21 02:00AM
Apr-27-21 02:00AM
Apr-26-21 02:00AM
Apr-13-21 05:00PM
Mar-22-21 03:00AM
Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and Rene Lafont on September 27, 2006 and is headquartered in Paris, France.